Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021
Sol-Gel Technologies (Nasdaq: SLGL) will report its second quarter 2021 financial results on August 4, 2021, at 7:05 AM ET. The company focuses on developing topical drug products for skin diseases, utilizing its microencapsulation technology platform. TWYNEO and EPSOLAY are under investigation for acne and rosacea, respectively, with NDAs filed with the FDA. However, the approval for EPSOLAY is delayed due to COVID-19 travel restrictions affecting the FDA's inspection of the production site.
- NDA filed for TWYNEO and EPSOLAY with the FDA.
- PDUFA goal dates set for August 1, 2021, and April 26, 2021, respectively.
- FDA unable to conduct a pre-approval inspection for EPSOLAY due to COVID-19 restrictions.
NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of TWYNEO® under investigation for the treatment of acne vulgaris with an NDA filed with the FDA and a PDUFA goal date set for August 1, 2021; and EPSOLAY®, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date set for April 26, 2021. Both product candidates are exclusively licensed for U.S. commercialization with Galderma Holding SA. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.
Contact:
Irina Koffler
Investor relations, LifeSci Advisors
ikoffler@lifesciadvisors.com
+1 917 734 7387
Sol-Gel Technologies
Gilad Mamlok
Chief Financial Officer
gilad.mamlok@sol-gel.com
FAQ
When will Sol-Gel Technologies report its Q2 2021 financial results?
What are the PDUFA goal dates for TWYNEO and EPSOLAY?
What caused the delay in EPSOLAY's approval?
What is Sol-Gel Technologies focused on developing?
